Get started
Author

Joel Shah

ORCID: 0000-0002-7428-5358
Observed ORCID: 0000-0002-7428-5358
OpenAlex ID: A5134150661
Accuracy, readability, and health information quality of AI chatbot responses for patient education on intermittent fasting in chronic kidney disease: a prospective structured evaluation
2026 · Joel Shah, William Wells-Gatnik, et al. · Frontiers in Nephrology · 1
PDF
Microvascular Dysfunction in Ischemia with No Obstructive Coronary Arteries (INOCA): Pathophysiology, Diagnosis, and Emerging Therapies
2026 · Sidhartha Senapati, Joel Shah, et al. · Cardiovascular & Haematological Disorders - Drug Targets · 1
Orforglipron and the Kidney: A Promise or Disappointment? The Need for Trials Examining Renal Outcomes
2026 · Joel Shah, Eder Luna Ceron, et al. · American Journal of Nephrology
Beyond erythropoiesis-stimulating agents: The evolving role of hypoxia-inducible factor stabilizers in anemia of chronic kidney disease
2026 · Joel Shah, William Wells-Gatnik, et al. · Clinical Nephrology
Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist
2026 · Prerana Ramadurgum, Joel Shah, et al. · Frontiers in Pharmacology
PDF
Artificial Intelligence—Enabled Hemodynamic Monitoring in Heart Failure: From Wearables to Predictive Decompensation Models
2026 · Sidhartha Gautam Senapati, Joel Shah, et al. · International Journal of Angiology
SGLT2 Inhibitors versus GLP-1 Receptor Agonists in Type 2 Diabetes, The Kidney Conundrum
2026 · Joel Shah · Clinical Journal of the American Society of Nephrology
Works count: 7
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type